Vaginal delivery in a patient with severe aortic stenosis under epidural analgesia, a case report by Driul, Lorenza et al.
CASE REPORT Open Access
Vaginal delivery in a patient with severe
aortic stenosis under epidural analgesia, a
case report
Lorenza Driul1,2, Francesco Meroi3,4* , Alessia Sala1,2, Silvia Delrio3,4, Daisy Pavoni5, Federico Barbariol4,
Ambrogio Londero2, Teresa Dogareschi4, Alessandra Spasiano4, Luigi Vetrugno3,4† and Tiziana Bove3,4†
Abstract
Background: A history of previous cardiac disease increases the maternal mortality risk by as much as 100%. There
is no consensus on the absolute contraindications to vaginal delivery in valvular heart disease, but central regional
anesthesia is traditionally considered contraindicated in patients with severe aortic stenosis.
Case presentation: A 29-year-old primigravid woman with severe aortic stenosis was admitted to the obstetrics
department for programmed labor induction. With epidural anesthesia and mini-invasive hemodynamic monitoring
labor and operative vaginal delivery were well tolerated, and hemodynamic stability was always maintained.
Conclusions: Epidural analgesia and oxytocin induction are possible for the labor management of parturients with
severe aortic stenosis given that continuous non-invasive followed by invasive hemodynamic monitoring can be
provided and given the absence of any obstetric or cardiologic contraindications and the strong will of the patient.
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Background
The management of pregnant patients with a history of
cardiac disease is challenging even for expert anesthesiolo-
gists. Although the prevalence of clinically relevant heart
disease is relatively low, occurring in approximately 1% of
pregnancies, major cardiac events occur in up to 13% of
pregnant patients with history of previous cardiac disease
[1]. Valvular heart disease accounts for approximately 40%
of these cases. The presence of a bicuspid aortic valve
with/without stenosis or insufficiency is the most preva-
lent defect, and represents the most common indication
for cardiac surgery in women of a fertile age [2].
Briefly from a physiological stand point, hormonal shifts
during pregnancy (specifically, the rise in progesterone
and prostacyclin) bring about significant hemodynamic
changes: systemic vascular resistance and blood pressure
decrease, whereas heart rate and stroke volume increase,
determining a rise in cardiac output [3].
The risk of cardiac complications is greatest during
the peripartum period, when factors such as uterine
contractions, pain, fatigue, bleeding, uterine involution
and anesthesia/analgesia may cause significant shifts in
hemodynamics, leading to acute heart failure [4]. There
is no consensus on the absolute contraindications to
vaginal delivery in valvular heart disease, but central re-
gional anesthesia is traditionally considered contraindi-
cated in patients with severe aortic stenosis [5].
Here we report on the management of a pregnant woman
with severe aortic stenosis who underwent labor with epi-
dural analgesia and close hemodynamic monitoring.
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Case presentation
A 29-year-old primigravid woman with severe aortic sten-
osis was admitted to the obstetrics department for pro-
grammed labor induction. She weighed 54 Kilograms (Kg),
was 160 cm (cm) high, and had no allergies. The patient had
undergone valvuloplasty at the age of 2 years for the correc-
tion of congenital aortic stenosis, followed by total valve re-
placement (with a biological prosthesis) at the age of 21.
Over the last 2 years (prior to and during her pregnancy),
the patient had presented episodes of supraventricular
tachycardia/atrial fibrillation, treated successfully with flecai-
nide. At the last echocardiography performed at 36weeks
and 4 days gestation, she presented a left ventricle with nor-
mal dimensions, thickness and systolic function, a biological
prosthesis on site with a thick and less mobile right coron-
ary cusp, and normal motility of the left coronary and non-
coronary cusps (Videos 1 and 2) with a maximum pressure
gradient of 52mmHg and an average of 31mmHg (Fig. 1).
The aortic valve area (AVA) was 0.9–1.0 cm2. She pre-
sented mild mitral insufficiency, an estimated pulmonary
systolic pressure of 27 mmHg and a normal left atrium
(Fig. 2). Electrocardiography revealed a normal sinus
rhythm (Fig. 3). The patient was medicated with enoxa-
parin, 4000 international units (IU), twice daily.
The patient was followed by the ‘high-risk pregnancy ser-
vice’ provided by our institution. Gestational age was calcu-
lated at the first trimester ultrasound scan. Her risk for
chromosomal anomalies was low, and early and late fetal
anomaly scans described normal fetal anatomy. An ultra-
sound scan performed at 35 weeks and 5 days gestation re-
vealed normal fetal parameters and growth and an
estimated fetal weight of 2888 g (65th percentile). A multi-
disciplinary team followed the patient, providing tailored
therapy (anticoagulation), and following evaluation (a de-
tailed obstetric visit and fetal weight estimation) the date of
delivery was set to 38weeks and 4 days of gestation. Con-
sidering the clinical history of the patient and her own pref-
erences, and in accordance with the obstetricians, we opted
for epidural labor analgesia. On the morning of the pro-
grammed labor induction, the patient’s vital parameters
were monitored: electrocardiography (ECG), oxygen sat-
uration (SpO2), non-invasive blood pressure (NIBP), and
cardiotocography. A defibrillator was ready and nearby.
We placed two large-bore intravenous catheters and
started infusion with Ringer’s acetate solution. We then
added a non-invasive hemodynamic monitoring system,
using the ClearSight™ and EV1000 Platform (Edwards
Lifesciences, Irvine, California, USA).
A trans-abdominal ultrasound scan with a convex probe
3.5MHz (Voluson E, GE Healthcare, Chicago, Illinois,
USA) showed a cephalic presentation, a maximal vertical
pocket (DVP) of 80mm, and an umbilical artery pulsatility
index (UA PI) of 0.80 (Figs. 4 and 5). Vaginal examination
revealed the cervix to be 2 cm dilated, 50% effaced, and to
have a Bishop Score of 6. The patient’s baseline vital
parameters were: heart rate (HR), 82 beats per minute
(bpm); median blood pressure (mAP), 85mmHg; SpO2,
100%; fetal heart rate (FHR), 159 bpm; cardiac index (CI), 4
L/min/m2; stroke volume index (SVI), 56ml/m2.
Her laboratory exams reported: 11.1 g/dL hemoglobin;
220.000 platelets; international normalized ratio (INR),
0.91; activated partial thromboplastin time ratio (aPTTr),
0.89; fibrinogen, 551 mg/dL. Enoxaparin therapy was
suspended 24 h before induction.
Using an 18-gauge (G) Tuohy needle, an epidural 20 G
catheter (B. Braun, Melsungen, Germany) was placed into
Fig. 1 Biological prosthesis aortic valve pressure gradient
Driul et al. Cardiovascular Ultrasound           (2020) 18:43 Page 2 of 8
lumbar (L) vertebral space 2–3 and tested with ropiva-
caine 0.2%, 5mL, fractionated into small boluses. All vital
parameters were constantly monitored and induction
started with a low dose oxytocin infusion (Table 1).
Five hours later, good progression of the first stage of
labor was evident, with 5 cm cervical dilation and good
effacement. An amniotomy was performed at this point.
The patient gave a pain rating of 5 out of 10 (using the
numeric pain rating scale, NPRS) and her hemodynamic
parameters were stable. We started with an epidural in-
fusion of ropivacaine 0.1%, 5 mL, and sufentanil, 3.75
mcg. After 30 min, the patient had a dermatomal level
around thoracic (T) spinal nerve T10 (Table 2).
During the following hours, we maintained an accept-
able level of analgesia, a constant dermatomal level, and
stable hemodynamic parameters with small boluses of
ropivacaine 0.1% and sufentanil, ranging from 5 to 10mL.
During this period, the dose of oxytocin was increased by
the obstetrician, and cervical dilation proceeded until
complete dilation. At this point, in order to guarantee ac-
curate hemodynamic monitoring, an artery line was put in
place and connected to the FloTrac™ system (Edwards
Lifesciences, Irvine, California, USA).
Three hours later, following episiotomy, the fetus was ex-
tracted using a vacuum (Kiwi Omni-C Cup, Ri.mos., Italy)
to avoid excessive exertion by the mother and in response
to initial alterations in the fetal cardiotocograph. Pain was
controlled with alkalinized lidocaine 2%, 4mL, given before
extraction, and all vital and hemodynamic parameters
remained stable (Table 1). A male baby weighing 3270 g was
Fig. 2 Pulmonary artery systolic pressure
Fig. 3 Electrocardiogram
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delivered with Apgar scores of 8 and 8 at minute 1 and 5,
respectively. Blood loss did not exceed 100mL. All the pa-
tient’s vital parameters were monitored for the next 10 h; we
then removed the epidural catheter and all other monitoring
devices and the patient was dismissed to the obstetrics ward
with stable parameters. Pain was treated with 1000mg para-
cetamol and 600mg ibuprofen every 8 h, with an NRS < 3.
The post-partum period was characterized by episodes of
fever and a suspected phlebitis of the hand. Considering the
high cardiovascular risk of the patient, the infectologist sug-
gested antibiotic therapy with daptomycin and piperacillin/
tazobactam, then de-escalated to amoxicillin-clavulanic acid
for a total of 20 days. One week after labor, echocardiog-
raphy was repeated and shown to be equivalent to the one
performed pre-partum. The patient was discharged from
the hospital 11 days post-partum.
Discussion
A history of previous cardiac disease increases the maternal
mortality risk by as much as 100% [6]. The most common
etiologies include congenital heart disease (~ 60%), valvular
heart disease (~ 30%), and cardiomyopathies (~ 6%), whereas
Fig. 4 Regular amniotic fluid and a maximal vertical pocket of 80 mm
Fig. 5 Umbilical artery pulsatility index
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ischemic heart disease, aortopathies, and pulmonary hyper-
tension account for a minority of cases (~ 4–5%) [7].
Peripartum cardiomyopathy is an idiopathic and rare heart
disease that manifests itself in the late phases of pregnancy
or early post-partum [8], with an incidence of one in 968
live births in American women [9]. It can clinically present
with congestion symptoms, such as dyspnea on exertion,
paroxysmal nocturnal dyspnea, orthopnea, and edema of
the lower extremities [10]. Cardiogenic shock occurs in a
small percentage of cases and less frequently unstable ar-
rhythmias and arterial thromboembolism [8, 11, 12]. Left-
and right-sided congestion are the typical clinical signs [8]
and echocardiography is the best diagnostic tool [13].
All women of a fertile age with a history of heart
disease should undergo pre-conception risk-assessment
and counseling in centers with high expertise for cardiac
diseases in pregnancy. Risk assessment should include
history and physical examination, 12-lead ECG, and
echocardiography. A cardiac CT scan or MRI and exer-
cise testing may be required in specific cases [14].
The most widely used risk assessment score is the modi-
fied version of the WHO classification, which takes into ac-
count the specific cardiac lesion and divides patients into
four classes of risk. Class I patients have no/mild risk, class II
and III patients have intermediate/high risk, and class IV pa-
tients are at very high risk (pregnancy contraindicated) [4].
Severe asymptomatic aortic stenosis, as present in the
patient of this case, is classified as WHO class III, with a
19–27% risk of maternal cardiac events. Expert counsel-
ing, monthly follow-ups during pregnancy, and delivery
in a specialized center are advised [4]. Figure 6 describes
the management of pregnancy and delivery in women
with heart disease.
Pregnancy is generally well tolerated in patients with mod-
erate or severe asymptomatic aortic stenosis, whereas symp-
tomatic severe stenosis patients are more likely to require
hospitalization. The most common complications are: heart
failure, pulmonary edema, and arrhythmias [15, 16]. Despite
the severity of our patient’s stenosis, she was asymptomatic
before conception and maintained a good functional status
throughout the pregnancy. Valvular gradients, as measured
by echocardiography, can increase during pregnancy due to
the physiological hemodynamic changes that occur.
Patients with a history of valve replacement carry a spe-
cific risk of prosthetic thrombosis (higher for mechanical
valves) and valve deterioration (in the case of biological
Table 1 Hemodynamic monitoring parameters recorded at: T0 = baseline, T1 = first epidural bolus, T2 = amniotomy, T3 = second
epidural bolus, T4 = third epidural bolus, T5 = complete dilation, T6 = fourth epidural bolus, T7 = delivery, T8 = 30 min after delivery,
T9 = 5 h after delivery, T10 = 10 h after delivery. HR = heart rate, MAP =median arterial pressure, CI = cardiac index, SVI = stroke
volume index, FHR = fetal heart rate, CD = cervical dilation, CE = cervical effacement, OXY = oxytocin, FS = fetal station
HR (bpm) MAP (mmHg) CI (L/min/m2) SVI (mL/m2) FHR (bpm) CD (cm) CE (%) OXY (mUI/min) FS (cm)
T0 82 85 4 56 159 2 50
T1 77 90 4.2 55 141 4 80 2.5
T2 69 107 4.2 60 140 5 80 7.5
T3 79 94 4.9 63 146 8 100 10 −2
T4 71 83 5.4 76 145 9 100 12.5 −1
T5 92 102 4.9 53 145 10 15
T6 74 99 4 55 147 10 17.5
T7 114 111 4.4 38 + 1
T8 78 110 3.6 46
T9 71 102 3.5 50
T10 74 105 3.4 45
Table 2 Labor analgesia protocol
Test dose after epidural catheter positioning Lidocaine 1%, 4 mL
First bolus Latent phase of labor Fentanyl 30–50 mcg (or sufentanil 5–7.5 mcg). Total volume 10 mL
Early labor stage Levobupivacaine 0.0625–0.1% (or ropivacaine 0.1–0.15%) + fentanyl
30 mcg (or sufentanil 5–7.5 mcg). Total volume 15–20 mL in 10 min
Active labor or labor
of a multipara
Levobupivacaine 0.1–0.125% (or ropivacaine 0.15–0.2%). Total
volume 15–20 mL in 10 min
Following doses Levobupivacaine 0.1% (or ropivacaine 0.1–0.15%) + fentanyl
1 mcg/mL (or sufentanil 0.25 mcg/mL). Total volume 15–20 mL
During delivery, before episiotomy,
before operative vaginal delivery
Lidocaine 1%, 10 mL
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valves). Bioprosthetic valves, like the one carried by our
patient, are usually advised in women of childbearing age
because of the lower requirement for anticoagulation ther-
apy [17, 18].
Although no RCTs have assessed the safety of epidural an-
algesia in patients with aortic stenosis (vasoplegia is of par-
ticular concern in patients highly dependent on pre-load),
some case reports exist describing the feasibility of epidural
analgesia to facilitate labor and minimize the pain-response
in obstetric patients with severe aortic stenosis [19, 20].
The management of induction and labor in a pregnant
woman with aortic stenosis depends on the grade of the
valvular stenosis (moderate or severe) and the presence of
symptoms. In asymptomatic patients with severe aortic
stenosis, it is important to consider an individual approach
[4]. The woman’s cardiac status, the fetus’s well-being,
and the cervix characteristics should all influence the
choice and timing of delivery. Although the rate of caesar-
ean section in patients with aortic stenosis is high, at 75%,
evidence exists suggesting that vaginal labor should be
preferred unless the obstetrician specifically advises
against it [15, 21]. Studies comparing methods of delivery
in patients with different heart diseases report caesarean
section rates to range from 21 to 55% [22, 23]. Moreover,
caesarean section is associated with a higher risk of ad-
verse outcomes in the mother [15], earlier delivery, a
lower birth weight, major blood loss, higher infection risk,
venous thrombosis, and thrombo-embolism [23].
Our case shows that labor induction combined with epi-
dural analgesia in a patient with a severe aortic stenosis is
possible. The patient was followed by adequate and
continuous hemodynamic and obstetric monitoring; she
showed no signs of heart failure, ventricular dysfunction,
pulmonary hypertension, or aortic dilation, and demon-
strated strong will throughout labor and childbirth.
Because of a favorable initial Bishop score, induction
was accomplished by starting with low doses of oxytocin
followed by artificial rupture of the membranes at a later
stage, showing that these methods of induction can be
safe in women with heart disease [4].
We chose to use the ClearSight™ hemodynamic monitor-
ing system during the first phase of labor to satisfy our re-
quirement for a fast and precise hemodynamic monitoring
device that was also non-invasive. For the second stage
of labor, we supplemented our system with arterial can-
nulation and the minimally-invasive FloTrac™ system
for beat-by-beat blood pressure and hemodynamic
monitoring. This permitted us to allow labor to progress
naturally, and uterine contractions alone facilitated the
descent of the fetus to the pelvic floor. However, when
continuous cardiotocography showed initial alterations,
vacuum extraction was performed. Our aim was to
minimize the maternal expulsive efforts, which could have
worsened her hemodynamic status, and reduced the
second stage of labor. We propose a clinical management
algorithm, as shown in Fig. 7 [24, 25].
Fig. 6 Management of pregnancy and delivery in women with heart disease. ECG = electrocardiogram, CT = computed tomography, MRI =
magnetic resonance imaging
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Conclusion
The case study herein reported demonstrates that
epidural analgesia and oxytocin induction are possible
for the labor management of parturients with severe aor-
tic stenosis given that continuous non-invasive followed
by invasive hemodynamic monitoring can be provided
and given the absence of any obstetric or cardiologic
contraindications and the strong will of the patient. A
protocol for prompt intervention must always be in
place to provide for the management of any potential
complications. A proactive approach is perhaps the most
appropriate for this kind of patient.
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